[go: up one dir, main page]

MX2015013832A - Composicion de vacuna y metodo de uso. - Google Patents

Composicion de vacuna y metodo de uso.

Info

Publication number
MX2015013832A
MX2015013832A MX2015013832A MX2015013832A MX2015013832A MX 2015013832 A MX2015013832 A MX 2015013832A MX 2015013832 A MX2015013832 A MX 2015013832A MX 2015013832 A MX2015013832 A MX 2015013832A MX 2015013832 A MX2015013832 A MX 2015013832A
Authority
MX
Mexico
Prior art keywords
vaccine composition
gla
protein
combination
adjuvant
Prior art date
Application number
MX2015013832A
Other languages
English (en)
Inventor
Stacie Lynn Lambert
Elizabeth Ann Stillman
Roderick Tang
Jennifer Chui Ling Woo
Gary Van Nest
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2015013832A publication Critical patent/MX2015013832A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C07K16/11—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se describe una composición de vacuna y métodos de uso. En una modalidad, la composición de vacuna incluye la proteína RSV-F en combinación con un adyuvante. En una modalidad más particular, la composición de vacuna incluye la proteína F soluble de RSV en combinación con un agonista del receptor tipo toll lipídico (TLR). En una modalidad más particular, el adyuvante comprende lípido A de glucopiranosilo (GLA). En una modalidad adicional, el adyuvante comprende GLA en una emulsión de aceite en agua estable (GLA-SE).
MX2015013832A 2013-04-08 2014-04-04 Composicion de vacuna y metodo de uso. MX2015013832A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361809563P 2013-04-08 2013-04-08
PCT/US2014/032938 WO2014168821A1 (en) 2013-04-08 2014-04-04 Vaccine composition and method of use

Publications (1)

Publication Number Publication Date
MX2015013832A true MX2015013832A (es) 2016-06-10

Family

ID=51689929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013832A MX2015013832A (es) 2013-04-08 2014-04-04 Composicion de vacuna y metodo de uso.

Country Status (13)

Country Link
US (1) US20160144021A1 (es)
EP (1) EP2983708A4 (es)
JP (1) JP2016516755A (es)
KR (1) KR20150139954A (es)
CN (1) CN105188748A (es)
AU (1) AU2014251247A1 (es)
BR (1) BR112015025392A2 (es)
CA (1) CA2909077A1 (es)
HK (2) HK1214138A1 (es)
MX (1) MX2015013832A (es)
RU (1) RU2015146762A (es)
SG (1) SG11201507978XA (es)
WO (1) WO2014168821A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
CN109982715A (zh) * 2016-09-27 2019-07-05 免疫疫苗技术有限公司 利用低剂量体积b细胞表位组合物以在受试人中诱导抗体免疫应答的方法
WO2018067300A1 (en) * 2016-10-03 2018-04-12 University Of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv)
KR20220074917A (ko) * 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
CN116199750A (zh) * 2023-01-06 2023-06-02 吉林大学 一种核糖体蛋白s11及制备方法和在疫苗佐剂中的应用
CN118063569B (zh) * 2024-04-24 2024-08-30 上海金翌生物科技有限公司 一种幽门螺杆菌分泌蛋白及其在检测幽门螺杆菌中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020018780A1 (en) * 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
US20060057104A1 (en) * 2002-04-24 2006-03-16 The Regents Of The University Of California Office Of The President Methods for stimulating tlr irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
MX2010007107A (es) * 2007-12-24 2010-12-21 Id Biomedical Corp Quebec Antigenos de virus del sincicio respiratorio recombinantes.
CA2766205A1 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
CA2766211A1 (en) * 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
CA2768186A1 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
EP2760469A4 (en) * 2011-09-30 2015-03-18 Novavax Inc RECOMBINANT RSV-F NANOPARTICLE VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS
KR102023791B1 (ko) * 2012-03-22 2019-09-23 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신

Also Published As

Publication number Publication date
SG11201507978XA (en) 2015-10-29
BR112015025392A2 (pt) 2017-10-10
WO2014168821A1 (en) 2014-10-16
HK1221641A1 (zh) 2017-06-09
AU2014251247A1 (en) 2015-11-05
US20160144021A1 (en) 2016-05-26
CN105188748A (zh) 2015-12-23
JP2016516755A (ja) 2016-06-09
EP2983708A1 (en) 2016-02-17
RU2015146762A (ru) 2017-05-16
KR20150139954A (ko) 2015-12-14
EP2983708A4 (en) 2016-10-05
HK1214138A1 (zh) 2016-07-22
CA2909077A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
MX2015013832A (es) Composicion de vacuna y metodo de uso.
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
CY1121990T1 (el) Φαρμακοτεχνικες μορφες αντισωματος υποδοχεα αντι-προλακτινης
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
SMT202100122T1 (it) Coniugati anticorpo-farmaco anti-cmet e metodi per il loro uso
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
CL2015001900A1 (es) Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2017007031A (es) Activacion de pestillo entre elementos.
MX2019004690A (es) Constructos de anticuerpos.
MX384824B (es) Compuestos conjugados antisentido y su uso.
AR104756A1 (es) Sistema para medir el cabello
MX2015016627A (es) Vacuna para la malaria.
CL2015002788A1 (es) Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario con el uso de un dispositivo móvil del usuario
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
CL2023002539A1 (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CR20160061A (es) Formulación estable líquida de etelcalcetide (amg 461)
EP2955192A4 (en) ANTI-MYCOPLASMA SPP. SUBUNIT VACCINE
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX384321B (es) Composición para administración oral de agentes bioactivos.
MX2016000235A (es) Metodos y composiciones para vacunas del virus del dengue.